Saturday, April 20, 2019
brThe U.S. Food and Drug Administration (FDA) recently released its draft guidance on managing cybersecurity in medical device premarket submissions. However, leading companies such as GE Healthcare and industry groups have voiced concerns over the tiered approach, saying this will result in confusion and potential discrepancies. They want the tiered system eliminated or amended. Industry
[ Read More ]Some of the associations submitting comments on FDA’s draft guidance suggested modifications to the agency’s call for a “cybersecurity bill of materials,” or CBOM, that medical device makers would need to submit to the FDA for premarket review. Some also critiqued FDA’s proposal to define two tiers of medical devices based on their cybersecurity risk
[ Read More ]At the Food and Drug Administration, the physician and venture investor promoted policies focused on innovating approaches to population health, opioids, chronic disease, AI and precision medicine. Despite the concerns of some that his close ties with the pharmaceutical industry offered the potential for “unprecedented financial entanglements with the industries he would regulate as FDA
[ Read More ]Released yesterday, the document outlines FDA’s preference toward single applications for combination products. The FDA released new draft guidance yesterday regarding premarket review for combination products those with a mix of components that span across the agencys drug, biologic and device product categories.The proposed premarket guidance, which may still be adjusted based on public feedback,
[ Read More ]A health monitoring watch being developed by Alphabet, Google’s parent company, has received 510(k) clearance from the U.S. Food and Drug Administration as a medical device. This means that the FDA has found the devices to be safe and effective, and that they can legally be sold in the US.
[ Read More ]Globalization reached healthcare big time: a French patient can easily ask a Belgian company to sequence the DNA of his tumor tissue, then convince a Swiss pharma company to sign them up for a relevant clinical trial on a Spanish island. Not only that but also the recent controversies around gene editing in babies in
[ Read More ]The Food and Drug Administration is sticking its toe in the water of artificial intelligence, providing its first guidance on the emerging development of applications for the technology in healthcare.The FDA released model 1.0 of its software precertification pilot Monday to provide an initial tool to test these programs. The agency noted that with AI
[ Read More ]Roche announced last week the launch of FoundationOne CDx, Foundation Medicines comprehensive companion diagnostic test for personalised cancer care in Singapore. According to the official media release, FoundationOne CDx supports clinicians in their decision-making by providing a clear, in-depth report that describes the unique genomic profile of a patients tumour as well as associated, approved
[ Read More ]To encourage healthcare technology innovation and update the 510(k) pathway, the regulatory agency said that it will soon release measures aimed to sunset predicate devices that are over a decade old. In the interest of promoting innovation, FDA Commissioner Dr. Scott Gottlieb and Dr. Jeff Shuren, director of the FDAs Center for Devices and Radiological
[ Read More ]The FDA is seeking public comments for a proposed framework that would allow the majority of apps and software released by pharmas that accompany a drug treatment to avoid lengthy premarket review submissions.According to a notice released last week, such software would be viewed as promotional labeling, and therefore only require submission to the FDAs
[ Read More ]
